Literature DB >> 15256808

Dose-response effects of estrogen and tamoxifen upon methamphetamine-induced behavioral responses and neurotoxicity of the nigrostriatal dopaminergic system in female mice.

Katherine R Mickley1, Dean E Dluzen.   

Abstract

In the present experiment we evaluated the dose-response effects of estrogen (estradiol benzoate; EB) and tamoxifen (TMX) in modulating the acute behavioral and chronic effects of methamphetamine (MA) upon the nigrostriatal dopaminergic (NSDA) system in ovariectomized (OVX) mice. EB over a range of doses from 1-40 microg resulted in a neuroprotective effect upon the NSDA system as defined by both a preservation of striatal dopamine (DA) concentrations and a decrease in DOPAC/DA ratios. Interestingly, the neuroprotective effect of the 1-microg EB dose occurred in the absence of any statistically significant effect upon the bioassay parameter of uterine weight. With the exception of an increase in stereotypy time as a response to the 40-microg dose, EB at any of the doses tested failed to alter any acute behavioral responses evoked by MA. In response to TMX, a statistically significant NSDA neuroprotectant response was obtained for DOPAC/DA ratios, but not DA concentrations, to doses ranging from 12.5 to 500 microg. No statistically significant effects upon uterine weights were obtained for any of the doses of TMX tested. Behaviorally, TMX at 500 microg had the effect of increasing the amount of time spent in the center of the cage. Taken together these results demonstrate: (1) EB and TMX at relatively low doses can exert a neuroprotective effect against MA; (2) these neuroprotective effects of EB and TMX can occur in the absence of an effect upon the bioassay parameter--uterine weights; (3) the parameter of DOPAC/DA ratio may indicate a more sensitive index of NSDA neuroprotection, and (4) modulatory effects of EB and TMX upon acute behavioral responses of the NSDA system to MA can be distinguished from their neuroprotective actions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15256808     DOI: 10.1159/000079710

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  9 in total

1.  Agonistic behavior in males and females: effects of an estrogen receptor beta agonist in gonadectomized and gonadally intact mice.

Authors:  Amy E Clipperton Allen; Cheryl L Cragg; Alexis J Wood; Donald W Pfaff; Elena Choleris
Journal:  Psychoneuroendocrinology       Date:  2010-02-02       Impact factor: 4.905

2.  Neuroprotective actions of selective estrogen receptor modulators.

Authors:  Lydia L DonCarlos; Iñigo Azcoitia; Luis M Garcia-Segura
Journal:  Psychoneuroendocrinology       Date:  2009-12       Impact factor: 4.905

3.  Rescue from Sexually Dimorphic Neuronal Cell Death by Estradiol and PI3 Kinase Activity.

Authors:  Hui-Yun Cheng; Shin-Hui Hung; Po-Ju Chu
Journal:  Cell Mol Neurobiol       Date:  2015-09-14       Impact factor: 5.046

4.  Blockade of MCH1 receptor signalling ameliorates obesity and related hepatic steatosis in ovariectomized mice.

Authors:  A Gomori; A Ishihara; M Ito; H Matsushita; M Ito; S Mashiko; H Iwaasa; M Matsuda; M A Bednarek; S Qian; D J Macneil; A Kanatani
Journal:  Br J Pharmacol       Date:  2007-05-21       Impact factor: 8.739

Review 5.  Estrogen receptor agonists for attenuation of neuroinflammation and neurodegeneration.

Authors:  Mrinmay Chakrabarti; Azizul Haque; Naren L Banik; Prakash Nagarkatti; Mitzi Nagarkatti; Swapan K Ray
Journal:  Brain Res Bull       Date:  2014-09-20       Impact factor: 4.077

6.  Selective estrogen receptor modulators regulate dendritic spine plasticity in the hippocampus of male rats.

Authors:  Ignacio González-Burgos; Martha C Rivera-Cervantes; Dulce A Velázquez-Zamora; Alfredo Feria-Velasco; Luis Miguel Garcia-Segura
Journal:  Neural Plast       Date:  2011-11-02       Impact factor: 3.599

7.  Male/Female differences in neuroprotection and neuromodulation of brain dopamine.

Authors:  Mélanie Bourque; Dean E Dluzen; Thérèse Di Paolo
Journal:  Front Endocrinol (Lausanne)       Date:  2011-09-30       Impact factor: 5.555

8.  Tamoxifen and the Risk of Parkinson's Disease in Female Patients with Breast Cancer in Asian People: A Nationwide Population-Based Study.

Authors:  Chien-Tai Hong; Lung Chan; Chaur-Jong Hu; Chien-Min Lin; Chien-Yeh Hsu; Ming-Chin Lin
Journal:  J Breast Cancer       Date:  2017-12-19       Impact factor: 3.588

9.  Delayed short-term tamoxifen treatment does not promote remyelination or neuron sparing after spinal cord injury.

Authors:  Nicole Pukos; Dana M McTigue
Journal:  PLoS One       Date:  2020-07-31       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.